The role of porcine factor VIII in the management of unexpected bleeding episodes.
The introduction of porcine factor VIII (pFVIII) has been an important addition to our armamentarium in the management of patients with inhibitors to FVIII. Case studies will be presented that offer important differential diagnoses. The prevalence and indications for the use of this biological replacement therapy will be discussed.
Aledort
L M
LM
Department of Hemophilia, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1006, New York, NY, USA.
D000328:Adult; D000818:Animals; D001323:Autoantibodies / Q000097:blood; D003937:Diagnosis, Differential; D019468:Disease Management; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007518:Isoantibodies / Q000097:blood; D008177:Lupus Vulgaris / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D008431:Maternal-Fetal Exchange / Q000276:immunology; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000276:immunology; D013552:Swine
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D005169:Factor VIII